SCHEMBL13637141

SCHEMBL13637141

Cc1cc(C(C)(C)C)nn1C(=O)N1CCS(=O)(=O)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 8/20 0.54
CNR2 P34972 6/20 0.42
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
KDM4E B2RXH2 1/20 0.35
GRN P28799 1/20 0.35
SORT1 Q99523 1/20 0.35
CDK8 P49336 2/20 0.33
RPS6KB1 P23443 1/20 0.32
SPR P35270 1/20 0.32
AURKA O14965 1/20 0.32
CSF1R P07333 1/20 0.32
RET P07949 1/20 0.32
LTK P29376 1/20 0.32
CSNK1A1 P48729 1/20 0.32
CLK2 P49760 1/20 0.32
CDK5 Q00535 1/20 0.32
ACVR1 Q04771 1/20 0.32
CLK4 Q9HAZ1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13315083 0.83 MAPK14 (0.54) MAPK14CNR2MAPK13MAPK12MAPK11
SCHEMBL14459897 0.77 MAPK14 (0.56) MAPK14CNR2MAPK13MAPK12MAPK11
SCHEMBL3551910 0.74 MAPK14 (0.74) MAPK14MAPK13MAPK12MAPK11
SCHEMBL3549246 0.72 MAPK14 (1.00) MAPK14MAPK13MAPK12MAPK11
SCHEMBL3541919 0.71 MAPK14 (1.00) MAPK14MAPK13MAPK12MAPK11
SCHEMBL13315081 0.67 MAPK14 (0.56) MAPK14CNR2MAPK13MAPK12MAPK11
SCHEMBL5853247 0.65 TSHR (0.49) KDM4E
SCHEMBL13487559 0.65 MAPK14 (0.53) MAPK14CNR2MAPK13MAPK12MAPK11
SCHEMBL27607371 0.65 ALDH1A1 (0.46) CNR2KDM4E
SCHEMBL17886574 0.64 CNR2 (0.42) MAPK14CNR2MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612200-B2 Inhibitors of protein kinases LOCUS PHARMACEUTICALS, INC. (US) 2009-11-03 US disclosed
US-20090192307-A1 INHIBITORS OF PROTEIN KINASES LOCUS PHARMACEUTICALS, INC. 2009-07-30 US disclosed
US-20070185098-A1 Inhibitors of protein kinases LOCUS PHARMACEUTICALS, INC. (US) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192307-A1 INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K19 MAPK14 300/4885CNR2 2502/4885MAPK13 418/4885
US-20070185098-A1 Inhibitors of protein kinases MAP3K20, MAP3K1, MAP3K19 MAPK14 300/4885CNR2 2502/4885MAPK13 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.